Clinical Trial Update: HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study [Phase 1]

View source ↗

Summary

Phase 1 study evaluating HBM4003 in combination with toripalimab in patients with advanced neuroendocrine tumors and other solid tumors, including colorectal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Neuroendocrine Tumors

Drugs mentioned

• HBM4003
• Toripalimab (Toripalimab)

Snippet

Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. | Conditions: Solid Tumors, Neuroendocrine Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING